KIT and osteosarcoma: However, clinical trials in osteosarcoma have shown that single‐target therapy, such as inhibiting VEGFs (with bevacizumab), KIT and PDGFRα (with imatinib), or IGF‐1R (with cixutumumab or R1507) has limited efficacy.